Abstract:Background The central nervous system (CNS) is the most common site of extramedullary invasion in acute lymphoblastic leukemia (ALL), and involvement of the CNS is often associated with relapse, refractory disease, and poor prognosis. Chimeric antigen receptor-T (CAR-T) cell therapy, a promising modality in cancer immunotherapy, has demonstrated significant advantages in the treatment of hematological malignancies. However, due to associated adverse reactions such as nervous system toxicity, the safety and efficacy of CAR-T cell therapy in treating CNSL remains controversial, with limited reports available. Case report Here, we present the case of a patient with confirmed B-ALL who experienced relapse in both bone marrow (BM) and cerebrospinal fluid (CSF) despite multiple cycles of chemotherapy and intrathecal injections. The infusion of autologous CD19 CAR-T cells resulted in complete remission (CR) in both BM and CSF for 40 days. However, the patient later experienced a relapse in the bone marrow. Subsequently, allogeneic CD19 CAR-T cells derived from her brother were infused, leading to another achievement of CR in BM. Significantly, only grade 1 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events were detected during the treatment period and showed improvement with symptomatic management. During subsequent follow-up, the patient achieved a disease-free survival of 5 months and was successfully bridged to hematopoietic stem cell transplantation. Conclusion Our study provides support for the argument that CNS involvement should not be deemed an absolute contraindication to CAR-T cell therapy. With the implementation of suitable management and treatment strategies, CAR-T therapy can proficiently target tumor cells within the CNS. This treatment option may be particularly beneficial for relapsed or refractory patients, as well as those with central nervous system involvement who have shown limited response to conventional therapies. Additionally, CAR-T cell therapy may serve as a valuable bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in these patients.

Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions

Diagnosis and treatment of acute leukemia with central nervous system infiltration

How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia

Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management

Central Nervous System Disease in Childhood Acute Lymphoblastic Leukemia

The CNS microenvironment promotes leukemia cell survival by disrupting tumor suppression and cell cycle regulation in pediatric T-cell acute lymphoblastic leukemia

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Diagnosis and treatment of central nervous system leukemia in acute lymphoblastic leukemia of children

Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia

Current Pharmacological Treatment Approaches to Central Nervous System Leukaemia

The diagnosis and treatment of central nervous system leukemia in adults with acute lymphoblastic leukemia

Prognostic significance of CNSL at diagnosis of childhood B-cell acute lymphoblastic leukemia: A report from the South China Children’s Leukemia Group

Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia

Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?

Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review

Current and emerging therapies for primary central nervous system lymphoma

Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas

Leukaemia cell intrinsic and extrinsic factors cooperate to facilitate the survival and proliferation of KMT2A-rearranged B-ALL in the CNS niche.

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children with Central Nervous System Leukemia

Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives

Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia